Drugs / TTK-567
last change Nov 2009 re-read 2 minutes ago

TTK-567

Peptide

Developed for
esophageal cancer
Investigated by
Human Genome Center, Institute of Medical Science, University of Tokyo · Wakayama Medical University

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00669292 Nov 2006 → Nov 2009 esophageal cancer Wakayama Medical University Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TTK-567 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00669292
Modality Peptide “TTK-567 peptide(1mg)” NCT00669292
Route Subcutaneous “will be administered by subcutaneous injection” NCT00669292